SGLT inhibitors for improving Healthspan and lifespan.

O'Keefe, James H; Weidling, Robert; O'Keefe, Evan L; Franco, W Grant

O'Keefe, James H; Weidling, Robert; O'Keefe, Evan L; Franco, W Grant.

Afiliação

O'Keefe JH; Saint Luke's Mid America Heart Institute and University of Missouri-Kansas City, Kansas City, MO, United States of America. Electronic address: jokeefe@saintlukeskc.org.
Weidling R; Saint Luke's Mid America Heart Institute and University of Missouri-Kansas City, Kansas City, MO, United States of America.
O'Keefe EL; Saint Luke's Mid America Heart Institute and University of Missouri-Kansas City, Kansas City, MO, United States of America.
Franco WG; Saint Luke's Mid America Heart Institute and University of Missouri-Kansas City, Kansas City, MO, United States of America.

Prog Cardiovasc Dis ; 81: 2-9, 2023.

Article em En | MEDLINE | ID: mdl-37852518

Assuntos

Diabetes Mellitus Tipo 2; Enfisema; Neoplasias; Doenças Neurodegenerativas; Inibidores do Transportador 2 de Sódio-Glicose; Humanos; Hipoglicemiantes; Longevidade; Glucose

Palavras-chave

Aging; Autophagy; Cardiovascular; Central nervous system; Geroprotection; Longevity; SGLTi; cancer

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Neurodegenerativas / Diabetes Mellitus Tipo 2 / Enfisema / Inibidores do Transportador 2 de Sódio-Glicose / Neoplasias Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google